Resveratrol exerts differential effects in vitro and in vivo against ovarian cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1333-1340

  Stakleff, K S ^a   Sloan, Tricia ^a   Blanco, Denise ^a   Marcanthony, Sharon ^a   Booth, Tristan ^b   Bishayee, Anupam ^c  

^a AKRON GENERAL MEDICAL CENTER   (United States)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c American University of Health Sciences   (United States)

Author keywords

Anti; Chemoprevention; Invasion effects; NuTu 19 cells; Ovarian cancer; Resveratrol

Indexed keywords

ANTINEOPLASTIC AGENT; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; APOPTOSIS; ARTICLE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECT; FEMALE; FISCHER 344 RAT; LUNG TUMOR; METASTASIS; OVARY TUMOR; PATHOLOGY; RAT; TUMOR CELL LINE;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; LUNG NEOPLASMS; OVARIAN NEOPLASMS; RATS; RATS, INBRED F344; STILBENES;

EID: 84873040404     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1333     Document Type: Article

References (62)

1. Aalto ML, Collan Y (1986). Periodic acid-Schiff stain as a prognostic indicator in serous and mucinous ovarian tumors. Int J Gynaecol Obstet, 24, 27-34.
2. Aggarwal BB, Bhardwaj A, Aggarwal RS, et al (2004). Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res, 24, 2783-40.
3. Athar M, Back JH, Kopelovich L, Bickers DR, Kim Al (2009). Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys, 486, 95-102.
4. Banerjee S, Bueso Ramos C, Aggarwal BB (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kB, cycloxygenase 2, and matrix metalloprotease 9. Cancer Res, 62, 4945-54.
5. Becher OJ, Holland EC (2006). Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res, 66, 3355-9.
6. Bishayee A (2009). Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res, 2, 409-18.
7. Bishayee A, Dhir N (2009). Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem-Biol Interact, 179, 131-44.
8. Bishayee A (2012). Current advances in cancer prevention and treatment by natural products. Curr Pharm Biotechnol, 13, 115-6.
9. Björklund M, Roos J, Gogvadze V, Shoshan M (2011). Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low dose-dose platinum treatment. Cancer Chemother Pharmacol, 68, 1459-67.
10. Bove K, Lincoln DW, Tsan MF (2001). Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun, 291, 1001-5.
11. Brard L, Granai CO, Swamy N (2006). Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecol Oncol, 100, 116-27.
12. Brewer MA, Johnson K, Follen M, Gershenson D, Bast R, Jr (2003). Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res, 9, 20-30.
13. Cao Z, Fang J, Xia C, Shi X, Jiang BH (2004). trans-3,4,5'-Trihydroxystibene inhibits hypoxia-inducible factor 1α and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res, 10, 5253-63.
14. Crowell JA, Korytko PJ, Morrissey Rl, Booth TD, Levine BS (2004). Resveratrol-associated renal toxicity. Toxicol Sci, 82, 614-9.
15. Delmas D, Solary E, Latruffe N (2011). Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med Chem, 18, 1100-21.
16. Dennis T, Fanous M, Mousa S (2009). Natural products for chemopreventive and adjunctive therapy in oncologic disease. Nutr Cancer, 61, 587-97.
17. Feki A, Jefford CE, Berardi P, et al (2005). BARD1 induces apoptosis by catalyzing phosphorylation of p53 by DNA-damage response kinase. Oncogene, 24, 3726-37.
18. Frémont L (2000). Biological effects of resveratrol. Life Sci, 66, 663-73.
19. Gescher AJ, Steward WP (2003). Relationship between mechanisms, bioavailability, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev, 12, 953-7.
20. Gullett NP, Ruhul Amin AR, Bayraktar S, et al. (2010) Cancer prevention with natural compounds. Semin Oncol, 37, 258-81.
21. Guo L, Peng Y, Yao J, (2010). Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice. Cancer Biother Radiopharm, 25, 471-7.
22. Harikumar KB, kunnumakkara AB, Sethi G, et al. (2010) Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer, 127, 257-68.
23. Harper CE, patel BB, Wang J, et al (2007). Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis, 28, 1946-53.
24. Hebbar V, Shen G, Hu R, et al. (2005) Toxicogenomics of resveratrol in rat liver. Life Sci, 76, 2299-314.
25. Hoekstra A, Rodriguez GC (2009). Chemoprevention of ovarian cancer. Cancer Treat Res, 149, 3-34.
26. Hsu SM, Raine L, Fanger H (1981). Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between (ABC) and unlabeled antibody (PAP) procedures. J Histochem Cytochem, 29, 577-80.
27. Jang M, Cai L, Udeani GO, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218-20.
28. Kueck A, Opipari AW, Griffith KA, et al. (2007) Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol, 107, 450-7.
29. Kundu JK, Surh YJ (2008). Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett, 269, 243-61.
30. Lee MH, Choi BY, Kundu JK, et al (2009). Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res, 69, 7449-58.
31. Li ZG, Hong T, Shimada Y, et al (2002). Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis, 23, 1531-6.
32. Lin C, Crawford DR, Lin S, et al. (2011) Inducible COX-2 dependent apoptosis in human ovarian cancer cells. Carcinogenesis, 32, 19-26.
33. Marimuthu P, Kaur K, Kandalam U, et al. (2011). Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation. J Med Food, 14, 46-52.
34. Medvetz DA, Stakleff KD, Schreiber T, et al. (2007) Ovarian cancer activity of cyclic amine and thiaether metal complexes. J Med Chem, 50, 1703-6.
35. Mills GB (2002). Mechanisms underlying chemoprevention of ovarian cancer. Clin Cancer Res, 8, 7-10.
36. s Development Panel on Ovarian Cancer (1995). Ovarian cancer: screening, treatment and follow-up. J Am Med Assoc, 273, 491-7.
37. Niles RM, Cook CP, Meadows GG, et al. (2006). Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr, 136, 2542-6.
38. Niles RM, Mcfarland M, Weimer MB, et al. (2003) Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett, 190, 157-63.
39. Opipari JR, AW, Tan L, et al (2004). Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res, 64, 696-703.
40. Park SY, Jeong KJ, Lee J, et al. (2007) Hypoxia enhances, LPA-induced HIF-1α and VEGF expression: their inhibition by resveratrol. Cancer Lett, 258, 63-9.
41. Raj MHG, Abd Elmageed ZY, Zhou J, et al (2008). Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells. Gynecol Oncol, 110, 432-8.
42. Rezk YA, Balulad SS, Keller RS, Bennett JA (2006). Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic can cell lines and in rodent heart. Am J Obstet Gynecol, 194, 23-6.
43. Rose GS, Toco LM, Granger GA, et al (1996) Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol, 175, 593-9.
44. Sankaranarayanan R, Ferlay J (2006). Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol, 20, 207-25.
45. Schneider Y, Duranton B, Gosse F, et al (2001) Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer, 39, 102-7.
46. Schumacher JJ, Dings RPM, Costin J, et al (2007). Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res, 67, 3683-90.
47. Sengottuvelan M, Viswanathan P, Nalini N (2006). Chemopreventive effect of trans-resveratrol - a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis, 27, 1038-46.
48. Shukla Y, Singh R (2011). Resveratrol and cellular mechanisms of cancer prevention. Ann NY Acad Sci, 1215, 1-8.
49. Siegel R, Naishadham, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
50. Sloan Stakleff KD, Rouse AG, Ryan AP, Haller NA, Von Gruenigen VE (2005). A novel early-stage orthotopic model for ovarian cancer in the Fischer 344 rat. Int J Gynecol Cancer, 15, 246-54.
51. Sloan Stakleff KD, Von Gruenigen VE (2003). Rodent models for ovarian cancer research. Int J Gynecol Cancer, 13, 405-12.
52. Smith ER, Daly MB, Xu XX (2004). A mechanism for cox-2 inhibitor anti-inflammatory activity in chemoprevention of epithelial cancers. Cancer Epidem Biomarkers Prev, 13, 144-5.
53. Stan SD, Kar S, Stoner GD, Singh SV (2008). Bioactive food components and cancer risk reduction. J Cell Biochem, 104, 339-56.
54. Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ (1997). Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med, 216, 201-10.
55. Subramanian L, Youssef S, Bhattacharya S, et al. (2010) Resveratrol: challenges in translation to the clinic - a critical discussion. Clin Cancer Res, 16, 5942-8.
56. Teicher BA (2006). Tumor models for efficacy determination. Mol Cancer Ther, 5, 2435-43.
57. Tessitore L, Davit A, Sarotto I, Caderni G (2000). Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21 (CIP) expression. Carcinogenesis, 21, 1619-22.
58. Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sciafani RA (2005). Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis, 26, 1978-87.
59. Visintin I, Feng A, Longton G, et al (2008). Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res, 14, 1065-72.
60. Weng CJ, Yen GC (2012). Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev, 38, 76-87.
61. Yang SH, Kim JS, Oh TJ, et al (2003) Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Int J Oncol, 22, 741-50.
62. Zhou H-B, Chen J-J, Wang W-X, Cai J-T, Du Q (2005). Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol, 11, 280-4.